Chinese Journal of Antituberculosis ›› 2024, Vol. 46 ›› Issue (7): 750-755.doi: 10.19982/j.issn.1000-6621.20240145
• Original Article • Previous Articles Next Articles
Chai Dongyu1, Qin Shuyi2, Zhang Ronghua2, Zou Nannan1, Wang Xin2()
Received:
2024-04-28
Online:
2024-07-10
Published:
2024-07-01
Contact:
Wang Xin
E-mail:wangxinconnie@163.com
Supported by:
CLC Number:
Chai Dongyu, Qin Shuyi, Zhang Ronghua, Zou Nannan, Wang Xin. Analysis of risk factors for viral pneumonia combined with invasive pulmonary mycosis[J]. Chinese Journal of Antituberculosis, 2024, 46(7): 750-755. doi: 10.19982/j.issn.1000-6621.20240145
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20240145
特征 | 观察组(105例) | 对照组(105例) | χ2值 | P值 |
---|---|---|---|---|
基础疾病 | ||||
高血压 | 60(57.1) | 57(54.3) | 0.174 | 0.677 |
冠心病 | 35(33.3) | 22(21.0) | 4.069 | 0.044 |
糖尿病 | 54(51.4) | 37(35.2) | 5.604 | 0.018 |
脑血管病 | 36(34.3) | 27(25.7) | 1.837 | 0.175 |
慢性阻塞性肺疾病 | 13(12.4) | 6(5.7) | 2.835 | 0.092 |
激素应用史 | 4(3.8) | 2(1.9) | 0.686 | 0.683 |
恶性肿瘤病史 | 27(25.7) | 7(6.7) | 14.037 | <0.001 |
慢性肾脏疾病 | 5(4.8) | 3(2.9) | 0.520 | 0.721 |
免疫抑制剂应用史 | 1(1.0) | 1(1.0) | 0.000 | 1.000 |
临床症状 | ||||
咳嗽/咳痰 | 99(94.3) | 100(95.2) | 0.096 | 0.757 |
发热 | 100(95.2) | 95(90.5) | 1.795 | 0.180 |
胸闷/胸痛 | 20(19.0) | 23(21.9) | 0.263 | 0.608 |
呼吸困难 | 65(61.9) | 42(40.0) | 10.080 | 0.001 |
咯血 | 4(3.8) | 2(1.9) | 0.686 | 0.683 |
体征 | ||||
肺部干啰音 | 30(28.6) | 12(11.4) | 9.643 | 0.002 |
肺部湿啰音 | 74(70.5) | 45(42.9) | 16.309 | <0.001 |
影像特征 | 观察组(105例) | 对照组(105例) | χ2值 | P值 |
---|---|---|---|---|
结节 | 30(28.6) | 28(26.7) | 0.095 | 0.758 |
单叶 | 13(12.4) | 14(13.3) | 0.043 | 0.837 |
多叶 | 17(16.2) | 12(11.4) | 1.000 | 0.317 |
实变 | 14(13.3) | 15(14.3) | 0.040 | 0.841 |
单叶 | 5(4.8) | 6(5.7) | 0.096 | 0.757 |
多叶 | 9(8.6) | 9(8.6) | 0.000 | 1.000 |
磨玻璃影 | 93(88.6) | 76(72.4) | 8.759 | 0.003 |
单叶 | 15(14.3) | 12(11.4) | 0.383 | 0.536 |
多叶 | 78(74.3) | 64(61.0) | 4.263 | 0.039 |
胸腔积液 | 46(43.8) | 20(19.0) | 14.937 | <0.001 |
单侧 | 8(7.6) | 4(3.8) | 1.414 | 0.373 |
双侧 | 38(36.2) | 16(15.2) | 12.066 | 0.001 |
淋巴结增大 | 26(24.8) | 13(12.4) | 5.322 | 0.021 |
指标 | 观察组(105例) | 对照组(105例) | 统计检验值 | P值 |
---|---|---|---|---|
合并细菌感染[例(感染率,%)] | 38(36.2) | 14(13.3) | χ2=14.722 | <0.001 |
白细胞计数[×109/L,M(Q1,Q3)] | 7.00(4.33,10.27) | 6.69(5.03,9.01) | Z=-0.035 | 0.972 |
中性粒细胞百分比[%,M(Q1,Q3)] | 81.00(72.90,89.15) | 76.70(65.35,85.00) | Z=-2.611 | 0.009 |
淋巴细胞百分比[%,M(Q1,Q3)] | 10.70(5.60,18.00) | 15.30(8.90,23.95) | Z=-2.774 | 0.006 |
C反应蛋白[mg/L,M(Q1,Q3)] | 47.84(15.30,87.10) | 33.45(9.83,68.43) | Z=-1.902 | 0.057 |
降钙素原[ng/ml,M(Q1,Q3)] | 0.11(0.04,0.39) | 0.09(0.04,0.21) | Z=-1.063 | 0.288 |
D-二聚体[mg/L,M(Q1,Q3)] | 1.61(1.01,3.10) | 1.05(0.59,1.44) | Z=-5.137 | <0.001 |
血清G试验阳性[例(阳性率,%)] | 25(23.8) | 3(2.9) | χ2=19.945 | <0.001 |
因素 | β值 | s | Wald χ2值 | P值 | OR(95%CI)值 |
---|---|---|---|---|---|
合并冠心病 | 0.581 | 0.413 | 1.979 | 0.159 | 1.789(0.796~4.021) |
合并糖尿病 | 0.897 | 0.380 | 5.568 | 0.018 | 2.452(1.164~5.163) |
恶性肿瘤病史 | 2.459 | 0.586 | 17.611 | <0.001 | 11.688(3.707~36.847) |
呼吸困难 | 0.332 | 0.399 | 0.690 | 0.406 | 1.393(0.637~3.046) |
肺干啰音 | 0.928 | 0.501 | 3.432 | 0.064 | 2.529(0.948~6.749) |
肺湿啰音 | 0.418 | 0.393 | 1.128 | 0.288 | 1.518(0.702~3.282) |
磨玻璃影 | 0.923 | 0.497 | 3.454 | 0.063 | 2.517(0.951~6.663) |
胸腔积液 | 0.910 | 0.405 | 5.046 | 0.025 | 2.484(1.123~5.494) |
淋巴结增大 | -0.495 | 0.493 | 1.006 | 0.316 | 0.610(0.232~1.603) |
合并细菌感染 | 1.206 | 0.440 | 7.505 | 0.006 | 3.341(1.410~7.920) |
中性粒细胞百分比 | 0.004 | 0.048 | 0.007 | 0.934 | 1.004(0.914~1.102) |
淋巴细胞百分比 | 0.016 | 0.056 | 0.080 | 0.777 | 1.016(0.911~1.133) |
D-二聚体 | 0.065 | 0.051 | 1.602 | 0.206 | 1.067(0.965~1.180) |
血清G试验阳性 | 2.614 | 0.730 | 12.835 | <0.001 | 13.649(3.267~57.029) |
常量 | -3.681 | 4.478 | 0.676 | 0.411 | 0.025 |
[1] |
Ruuskanen O, Lahti E, Jennings LC, et al. Viral pneumonia. Lancet, 2011, 377(9773):1264-1275. doi:10.1016/S0140-6736(10)61459-6.
pmid: 21435708 |
[2] |
Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med, 2018, 6(10): 782-792. doi:10.1016/S2213-2600(18)30274-1.
pmid: 30076119 |
[3] | Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med, 2019, 200(7): e45-e67. doi:10.1164/rccm.201908-1581ST. |
[4] | 中华医学会呼吸病学分会感染学组, 中华结核和呼吸杂志编辑委员会. 肺真菌病诊断和治疗专家共识. 中华结核和呼吸杂志, 2007, 30(11):821-834. doi:10.3760/j.issn:1001-0939.2007.11.008. |
[5] | 张国良, 瞿介明. 呼吸感染性疾病诊治年度进展2023. 中华结核和呼吸杂志, 2024, 47(2):141-146. doi:10.3760/cma.j.cn112147-20231117-00317. |
[6] |
Schwartz IS, Friedman DZP, Zapernick L, et al. High Rates of Influenza-Associated Invasive Pulmonary Aspergillosis May Not Be Universal: A Retrospective Cohort Study from Alberta, Canada. Clin Infect Dis, 2020, 71(7):1760-1763. doi:10.1093/cid/ciaa007.
pmid: 31905235 |
[7] |
Short KR, Kasper J, van der Aa S, et al. Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions. Eur Respir J, 2016, 47(3):954-966. doi:10.1183/13993003.01282-2015.
pmid: 26743480 |
[8] |
Herold S, Becker C, Ridge KM, et al. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur Respir J, 2015, 45(5):1463-1478. doi:10.1183/09031936.00186214.
pmid: 25792631 |
[9] | Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis, 2020, 71(15):762-768. doi:10.1093/cid/ciaa248. |
[10] | Feys S, Gonçalves SM, Khan M, et al. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study. Lancet Respir Med, 2022, 10(12):1147-1159. doi:10.1016/S2213-2600(22)00259-4. |
[11] | Ni H, Yu H, Lin Q, et al. Analysis of risk factors of fungal superinfections in viral pneumonia patients: A systematic review and meta-analysis. Immun Inflamm Dis, 2023, 11(1):e760. doi:10.1002/iid3.760. |
[12] | Shi C, Shan Q, Xia J, et al. Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: A systematic review and meta-analysis. Mycoses, 2022, 65(2):152-163. doi:10.1111/myc.13410. |
[13] | Lao M, Li C, Li J, et al. Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China: Clinical features and associated factors. J Diabetes Investig, 2020, 11(3):731-744. doi:10.1111/jdi.13183. |
[14] |
Azoulay E, Russell L, Van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Med, 2020, 46(2):298-314. doi:10.1007/s00134-019-05906-5.
pmid: 32034433 |
[15] | Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis, 2021, 21(6):e149-e162. doi:10.1016/S1473-3099(20)30847-1. |
[16] | Wei H, Li Y, Han D, et al. The values of (1,3)-β-D-glucan and galactomannan in cases of invasive fungal rhinosinusitis. Am J Otolaryngol, 2021, 42(2):102871. doi:10.1016/j.amjoto.2020.102871. |
[17] |
Verweij PE, Rijnders BJA, Brüggemann RJM, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med, 2020, 46(8):1524-1535. doi:10.1007/s00134-020-06091-6.
pmid: 32572532 |
[1] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[2] | Zhang Guoqin, Qu Ting, Meng Qinglin, Zhou Lin, Liu Eryong. Implementation update of strategy for the control of tuberculosis and HIV/AIDS co-infection in China [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 12-17. |
[3] | Yang Liangzi, Zhang Peize, Lu Shuihua. Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 874-876. |
[4] | Cai Qinghe, Fu Hui, Chen Ruiming, Fan Youming, Yang Qingwei. Analysis of the clinical characteristics and influencing factors of pulmonary tuberculosis patients with diabetes mellitus in Shantou City from 2016 to 2022 [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 926-934. |
[5] | Fu Keyan, Zhu Bangzheng, Ye Jian. Research progress on interstitial lung disease combined with Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 823-829. |
[6] | Liu Guizhen, Deng Guofang. Interpretation of Evidence and research gaps identified during development of policy guidelines for tuberculosis (Second edition): tuberculosis related comorbidity [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 618-624. |
[7] | Li Yao, Fang Zhe, Luo Danlin, Hu Yanmei, Tang Mi, Tang Zhigang, Wen Xinmin, Zhang Yong, Yao Bibo, Wang Qi, Yi Hengzhong. Clinical characteristics and prognosis of patients with novel coronavirus infection complicated with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 687-698. |
[8] | Yang Rui, Li Ling, Chen Jinou, Xu Lin. Analysis of influencing factors of anti-tuberculosis treatment effect for pulmonary tuberculosis patients complicated with diabetes in Yunnan Province from 2017 to 2021 [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 519-524. |
[9] | Liu Meijun, Li Feng. Current situation and research progress of co-infection of HIV/AIDS and subclinical tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 596-600. |
[10] | Yang Jieying, Xiao Xincai, Du Yuhua, Lai Keng, He Liqian, Wang Ting, Lin Ying, He Weiyun. Analysis of epidemiological characteristics and therapeutic prognosis among pulmonary tuberculosis patients complicated with diabetes mellitus in Guangzhou City from 2014 to 2023 [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1504-1510. |
[11] | Sun Qingfeng, Li Haoran, Pang Yu, Gao Mengqiu. Co-morbidity research progress of tuberculosis and depression [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 106-111. |
[12] | Liu Qiliang, Li Yuejie, Lei Mei. Clinicopathological features of 13 cases cervical lymph node tuberculosis complicated with metastatic carcinoma [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 891-896. |
[13] | Zhang Pei, Zhao Ahui, Gao Min, Zhen Xinan, Yao Yuxia, Jiang Jianguo, Sun Jianwei, Sun Dingyong. Epidemiological characteristics of MTB/HIV co-infection in Henan from 2016 to 2021 [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 377-382. |
[14] | Dai Zhenwei, Zhang Haoran, Jing Shu, Xiao Weijun, Wang Hao, Huang Yiman, Chen Xu, Fu Jiaqi, Wu Yijin, Gao Lei, Su Xiaoyou. Effect of mindfulness level on mental health of middle-aged and elderly people with type 2 diabetes mellitus comorbidity latent tuberculosis infection in rural areas [J]. Chinese Journal of Antituberculosis, 2023, 45(2): 188-194. |
[15] | Han Tingting, Liu Guizhen, Chen Qiuqi, Deng Guofang. Interpretation of Framework for collaborative action on tuberculosis and comorbidities [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 25-30. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||